I think the cash balance is a concern . Enough for Nuedetra to turn break even but not enough to carry clinical trials. Hoping for EU approval with some up front cash of 50 to 100 million . should be more but depends on reinbursements and possible labling restrictions.
No I am not a pretend long , so give it a break. Just trying to have an intelligent conversation about the short term prospects.
I actually think the stars are lining up perfectly here for AVNR.........cash is a minor but growing concern. When EU approval and a partner / joint venture shows up (before end of '13) we will get up front $$ to tide us over until N becomes profitable and can support all other research.
"No I am not a pretend long , so give it a break. Just trying to have an intelligent conversation about the short term prospects."
LOL....Good luck with that. You soon figure out there are large number of over-invested starry eyed pumpers here that will attack you for expressing any kind of concern or attempt at trying to understand why the launch and uptake of N has SUCKED. They will resort to lying - like the latest post from frustrated pumper extraordinaire - mikie24 - who accuses me of posting 100's of times per week. A quick review of my posting history quickly reveals yet another lie about me.
The list of AVNR message board idiots is long with Jean Dumb Dumb on the top. And there are just as many idiot short bashers on here as well. Unfortunately they make posting on this board a playground for themselves.